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Background: In Europe cardiovascular disease (CVD) is responsible for 3.9 million deaths (45% 
of deaths), being ischaemic heart disease, stroke, hypertension (leading to heart failure) the 
major cause of these CVD related deaths. Periodontitis is also a chronic non‐communicable 
disease (NCD) with a high prevalence, being severe periodontitis, affecting 11.2% of the world’s 
population, the sixth most common human disease.
Material and Methods: There is now a significant body of evidence to support independent 
associations between severe periodontitis and several NCDs, in particular CVD. In 2012 a joint 
workshop was held between the European Federation of Periodontology (EFP) and the American 
Academy of Periodontology to review the literature relating periodontitis and systemic diseases, 
including CVD. In the last five years important new scientific information has emerged providing 
important emerging evidence to support these associations.
Results and Conclusions: The present review reports the proceedings of the workshop 
jointly organised by the EFP and the World Heart Federation (WHF), which has updated the 
existing epidemiological evidence for significant associations between periodontitis and CVD, 
the mechanistic links and the impact of periodontal therapy on cardiovascular and surrogate 
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outcomes. This review has also focused on the potential risk and complications of periodontal 
therapy in patients on anti thrombotic therapy and has made recommendations for dentists, 
physicians and for patients visiting both the dental and medical practices.
Keywords: Periodontitis; periodontal therapy; cardiovascular diseases; chronic inflammation; 
bacteremia; atherosclerosis; antitrombotic therapy
1. Introduction
Non-communicable diseases (NCDs) are rising in prevalence globally in line with an increasingly ageing 
population, refined diets and sedentary lifestyles. NCDs account for 41 million deaths each year, or 71% of 
all global deaths [40]. Approximately 80% of people over the age of 65 in the USA are affected by one or 
more NCDs, and 77% exhibit at least two NCDs, creating a significant burden of disease to individuals and 
to the healthcare economy [13]. The co-morbid presence of two or more NCDs presents a major challenge 
to the economy, equating to two thirds of all health costs in the USA [14]; however, less than 1% of health 
expenditure in the USA is focussed on prevention to improve overall health [129].
The greatest global NCD burden arises due to cardiovascular disease (CVD), which is responsible for 
17.9 million deaths (one third of total mortality) and 45% of NCD-induced mortality [104]. In Europe, 
CVD is responsible for 3.9 million deaths (45% of deaths), and whilst CVD mortality rates are reducing, 
the absolute numbers have increased in the last 25 years due to an increasingly ageing population [135]. 
Ischaemic heart disease, stroke, hypertension (leading to heart failure), rheumatic heart disease, cardio-
myopathy and atrial fibrillation cause over 95% of CVD-related deaths [103].
In this consensus report, the term CVD is used as a general term for atherosclerotic diseases, principally 
coronary heart disease, cerebrovascular disease and peripheral vascular disease. A number of chronic 
infectious-inflammatory-immune diseases are associated with significantly higher risks of adverse car-
diovascular events, including rheumatoid arthritis, psoriasis, systemic lupus erythematosus and peri-
odontitis [103], consistent with the thesis that chronic elevations in the systemic inflammatory burden 
are causally related to CVD development and its sequelae. Whilst there is evidence for over 50 gene 
polymorphisms playing a role in the modulation of atherogenesis [46], effect sizes are small and the 
major traditional risk factors for CVD remain lifestyle factors, principally tobacco smoking, dyslipidaemia, 
hypertension and altered glucose metabolism. The latter correlate strongly with diets high in saturated 
fats, salt and refined sugars and contribute to obesity and type 2 diabetes mellitus, major attributable risk 
factors for myocardial infarction [50]. The same risk factors account for over 90% of the stroke burden 
[87], yet all are modifiable through improved lifestyles, including reducing salt, saturated fat and refined 
carbohydrate intake, exercising, increasing intake of antioxidant micronutrients and regular moderate 
alcohol consumption [50].
Periodontitis is also an NCD with a high prevalence of 45–50% overall, with the most severe form affecting 
11.2% of the world’s population, making it the sixth most common human disease [52]. The Global Burden 
of Diseases, Injuries, and Risk Factors Study (2017) of Years Lost to Disability (YLD) reported that from 1990 
to 2017 oral diseases (mainly periodontitis and caries) contributed the most YLD in age-standardised preva-
lence rates from 354 diseases and injuries across 195 countries [39]. There is now a significant body of 
evidence to support independent associations between severe periodontitis and several NCDs, including 
diabetes [17], cardiovascular disease [128], chronic obstructive pulmonary disease [64] and chronic kid-
ney disease (CKD) [117]. Indeed, severe periodontitis is independently and significantly associated with all-
cause and cardiovascular mortality in several different populations [63, 117]. Proposed mechanisms include 
bacteraemia and the associated systemic inflammatory sequelae, including elevations in C-reactive protein 
and oxidative stress [113]. In populations with multi-morbidity, for example chronic kidney disease with 
co-morbid diabetes and periodontitis, periodontitis is associated with significantly reduced survival from 
all-cause and cardiovascular mortality [117]. It appears, therefore, that periodontitis may be a modifiable 
non-traditional risk factor for CVD.
In 2012 a joint workshop was held between the European Federation of Periodontology (EFP) and the 
American Academy of Periodontology to review the literature relating periodontitis and systemic diseases, 
including CVD. The consensus report was based upon four technical papers that systematically reviewed 
the evidence for epidemiological associations between periodontitis and incident CVD [28], mechanisms 
of biological plausibility relating to periodontal bacteria and systemic inflammation [101, 113] and peri-
odontal intervention studies [23]. The workshop concluded there was consistent and strong epidemiological 
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evidence that periodontitis imparts increased risk for future atherosclerotic cardiovascular disease. It also 
concluded the impact of periodontitis on CVD was biologically plausible, via translocated circulating oral 
microbiota, which may directly or indirectly induce systemic inflammation that impacts upon the develop-
ment of atherothrombogenesis, and whilst in vitro, pre-clinical and clinical studies supported the inter-
action and associated biological mechanisms, intervention trials were not sufficiently adequate to draw 
further conclusions at that time.
The present workshop was jointly organised by the EFP and the World Heart Federation (WHF) to include 
global experts in both periodontal and cardiovascular disciplines and was held in Madrid on 18 and 19 
February 2019. Four technical reviews updating the evidence base from the 2012 workshop were prepared 
and supplemented by additional studies discussed at the workshop. The reviews focussed on epidemiologi-
cal associations [45], mechanistic links [114], results from intervention studies [89] and the potential risk 
and complications of periodontal therapy in patients undertaking antithrombotic (antiplatelet and antico-
agulant) therapy.
While this consensus report focuses predominantly on relevant evidence published since the 2012 work-
shop, there are biological areas that have subsequently come to prominence, and where the underpinning 
body of evidence was not covered in the 2013 consensus report; hence, certain pre-2012 manuscripts are 
referenced to ensure the context of these recent studies is clear.
Furthermore, sections 4.3: What is the effect of statin intake on clinical periodontal outcomes? and 
 section 5: Cardiovascular risks and complications of periodontal therapeutic interventions were not dealt 
with in the previous workshop; hence, a full appraisal of the scientific evidence was carried out in this 
consensus meeting.
Finally, following the review of the presented evidence, recommendations for both medical and dental 
teams, as well as patients and the public, were elaborated.
2. Epidemiologic evidence on the association between periodontitis and CVD
2.1. Do people with periodontitis have a higher prevalence of subclinical cardio-
vascular disease?
There is evidence from epidemiological studies that periodontitis patients exhibit significant endothelial 
dysfunction, measured by flow mediated dilation (FMD), arterial stiffness (e.g., pulse wave velocity – PWV) 
and a significantly greater thickness of the carotid intima media (cIMT) and elevated arterial calcification 
scores. There is one imaging study (ATHEROREMO-IVUS study) associating high levels of antibodies against 
periodontal pathogens and a lower extent of positive atheromatous plaque remodelling [24].
2.2. Do people with periodontitis have a higher prevalence of coronary artery 
disease and risk of myocardial infarction and other coronary events?
There is robust evidence from epidemiological studies for a positive association between periodontitis and 
coronary heart disease. A systematic review [28], which was updated in preparation for this workshop, 
identified a total of six case-control and cohort epidemiological studies, published in the last five years, which 
demonstrated an increased risk of a first coronary event in patients with clinically diagnosed periodontitis 
or more severe periodontitis compared to patients without periodontitis or less severe periodontitis. 
Relative risk estimates vary between studies, depending on population characteristics and periodontitis 
case definitions. There are two cohort studies reporting an association between periodontitis and higher 
cardiovascular mortality (due to coronary heart disease and cerebrovascular disease).
2.3. Do people with periodontitis have a higher prevalence of cerebrovascular 
disease and risk of stroke?
There is evidence from epidemiologic studies for a positive association between periodontitis and cerebro-
vascular disease. A systematic review [28], which was updated in preparation for this workshop, identified a 
total of three case-control and cohort studies, which demonstrate an increased risk of a first cerebrovascular 
event in patients with clinically diagnosed periodontitis or more severe periodontitis compared to patients 
without periodontitis or less severe periodontitis. Relative risk estimates vary between studies, depending on 
population characteristics and periodontitis case definitions. Furthermore, a recent analysis of data from the 
Atherosclerosis Risk in Communities (ARIC) study demonstrated an association between periodontal profile 
class and incident ischemic stroke. In this cohort, patients with periodontitis had more than double the risk 
of cardioembolic and thrombotic stroke compared to periodontally healthy individuals [115]. In addition, 
as previously documented, there are two cohort studies reporting an association between periodontitis and 
higher cardiovascular mortality (due to coronary heart disease and cerebrovascular disease) [28].
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2.4. Do people with periodontitis have a higher prevalence and incidence of 
Peripheral Artery Disease (PAD)?
There is limited but consistent evidence that individuals with periodontitis have a higher prevalence and 
incidence of PAD compared to individuals without periodontitis [140]. For cross-sectional data, the most 
significant evidence comes from two large, population-based studies in the USA (NHANES 1999–2002) 
and South Korea (KoGES-CAVAS). Both studies found a positive association between the extent of clinical 
attachment loss (NHANES 1999–2002) and severity of radiographic bone loss (KoGES-CAVAS) with PAD, 
defined using the Ankle Brachial Index (ABI), with adjusted odd ratios (OR) of 2.2 (95% confidence interval 
-CI-; [1.2; 2.4]) and 2.0 (95% CI [1.1; 3.9]), respectively [2, 70]. One prospective cohort study, conducted in 
male veterans in the USA, reported a positive association between periodontitis (measured by severity of 
radiographic bone loss) and the incidence of PAD over a 25–30 year follow-up period, with an adjusted OR 
of 2.3 (95% CI [1.3; 3.9]) [77]. There are no studies that have evaluated the association between periodon-
titis and the incidence of Major Adverse Limb Events (MALE).
2.5. Do people with periodontitis have a higher risk of other CVDs or conditions 
(heart failure, atrial fibrillation)?
Several studies report positive associations between periodontitis and heart failure. There is evidence from 
a large Asian study using the Taiwanese National Health Insurance Research Database reporting a signifi-
cantly higher incidence of atrial fibrillation in individuals with periodontal diseases compared to individuals 
 without periodontal diseases (hazard ratio –HR = 1.31, 95% CI [1.25; 1.36]) [18].
2.6. Do people with a history of cardiovascular disease have a different incidence 
or progression of periodontitis?
There is currently limited scientific evidence that CVD is a risk factor for the onset or progression of 
 periodontitis.
2.7. Do people with periodontitis with history of cardiovascular disease have a 
higher chance of experiencing a subsequent event?
From three studies investigating the association between periodontitis and secondary cardiovascular 
events, two large studies did not find a significant association [31, 100]; however, a small study (100 
subjects) reported a significant association (HR = 2.8, 95% CI [1.2; 6.5]) with recurrent cerebro-vascular 
events [116].
3. Mechanisms that may explain the epidemiological associations between 
periodontitis and CVD
3.1. Is there evidence of a higher incidence of bacteremia following oral 
 function/intervention in periodontitis patients compared to periodontally 
healthy subjects?
There is evidence that oral bacterial species can enter the circulation and cause bacteremia, which has been 
demonstrated following daily life activities (tooth brushing, flossing, chewing or biting an apple), although 
it has been studied more frequently following professional interventions (tooth polishing, scaling, tooth 
extraction, surgical extraction of third molars and periodontal probing).
The risk of bacteremia has been associated with periodontal health status in a systematic review, suggest-
ing a higher risk of bacteremia associated with gingival inflammation [127]. A recent randomized clinical 
trial (RCT) concluded that periodontal therapy (by means of scaling and root planing, SRP) induced bacte-
remia in both gingivitis and periodontitis patients, but the magnitude and frequency were greater among 
periodontitis patients [5].
Whilst there are methodological limitations in some of the reported studies, the overall picture supports 
the contention that bacteremia results from daily life activities and oral interventions, and it is more fre-
quent, of longer duration and involves more virulent bacteria in periodontitis patients.
3.2. Is there evidence for the presence of oral bacteria in atheroma lesions?
There is evidence through traces of DNA, RNA or antigens derived from oral bacterial species, mainly 
periodontal pathogens, that have been identified in atherothrombotic tissues. Studies have attempted 
to correlate the presence of these bacteria in atherothrombotic tissues with other sample sources (sub-
gingival plaque, serum, etc.) in the same patients, and these suggest that in periodontitis patients there 
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is a higher probability of a positive correlation [3, 73]. At least two studies have demonstrated viable 
P. gingivalis and A. actinomycetemcomitans in athero-thrombotic tissue when culturing the atheroma 
samples [56, 98].
3.3. Do we have evidence that periodontal bacteria and/or bacterial products and 
virulence factors influence the pathophysiology of atherosclerosis?
Different animal models have been employed to provide evidence that periodontal pathogens can promote 
atheroma formation. P. gingivalis has been shown to accelerate atherosclerosis in murine models, to induce 
fatty streaks in the aorta of rabbits and to induce aortic and coronary lesions after bacteremia in normocho-
lesterolaemic pigs (Schenkein & Loos. 2003).
Recently, further evidence has emerged using hyperlipidemic ApoEnull mice after infection with P. gin-
givalis and also with a polymicrobial experimental infection (P. gingivalis, Treponema denticola, Tannerella 
 forsythia and Fusobacterium nucleatum). A polymicrobial infection was shown to induce aortic toll-like 
receptor (TLR) and inflammasome signaling, with an enhanced oxidative stress reaction generated within 
the aortic endothelial cells [20, 131, 132].
There is also in vitro evidence of intracellular entry by periodontal pathogens (P. gingivalis, A. actino-
mycetemcomitans, etc.) [101]. In vivo and in vitro studies demonstrate the importance of the fimbriae 
of P. gingivalis to host cell entry and to promote atherothrombotic lesions in experimental models 
[138]. In vitro experiments have shown certain bacterial strains expressing P. gingivalis hemagglutinin 
A (HagA) have an increased capability to adhere and enter human coronary artery endothelial cells 
(HCAEC) [7].
3.4. Do we have evidence that periodontitis patients exhibit increased production 
and/or levels of inflammatory mediators also associated with the pathophysiology 
of atherosclerosis?
There is evidence of significantly higher levels of C-reactive protein (CRP) in periodontitis patients versus 
healthy controls and in CVD and periodontitis patients compared with either condition alone. The effect 
of periodontal therapy has been shown to associate with a significant decrease in CRP levels, along with 
improvements in surrogate measurements of cardiovascular health [27, 55, 93].
There is evidence of elevated levels of serum interleukin (IL)-6 in periodontitis patients and lower levels 
of IL-4 and IL-18. The effect of periodontal therapy has shown a significant decrease in the serum levels of 
IL-6, serum amyloid A and alpha 1 anti-chymotripsin. Peripheral neutrophils from periodontitis patients 
release excess IL-1β, IL-8, IL-6 and tumour necrosis factor (TNF)-α when stimulated by periodontal patho-
gens. Periodontal therapy only partially reduces the cytokine hyperreactivity with some evidence of a con-
stitutively elevated response [66].
3.5. Do we have evidence that periodontitis patients develop elevations in 
thrombotic factors that are also associated with the pathophysiology of athero-
thrombosis?
There is evidence of significantly higher levels of fibrinogen in periodontitis patients versus healthy con-
trols and in CVD and periodontitis patients compared with either condition alone [15]. Periodontal therapy 
appears to result in a significant decrease in fibrinogen levels [69, 133].
There is evidence from different studies of significantly higher levels of platelet activation markers in peri-
odontitis patients and that these higher levels may be reversed by periodontal therapy [4]. However, there 
is conflicting evidence that significantly higher levels of plasminogen activator inhibitor (PAI) are found in 
periodontitis patients (Schenkein & Loos. 2003).
3.6. Do we have evidence that periodontitis patients demonstrate elevated serum 
antibody levels that cross-react with antigens in cardiovascular tissues?
There is evidence that Heat Shock Proteins (HSP) from periodontal pathogens (Porphyromona gingivalis, 
Tannerella forsythia, Aggregatibacter actinomycetemcomitans and Fusobacterium nucleatum) generate anti-
bodies that can cross-react with human HSPs. These antibodies have been shown to activate cytokine pro-
duction, as well as monocyte and endothelial cell activation.
Presence of anti-cardiolipin antibodies have been significantly associated in periodontitis patients, which 
reversed following periodontal therapy. There is some evidence that periodontal pathogens can elicit anti-
bodies that cross-react with cardiolipin (Schenkein & Loos. 2003).
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In three out of four population-based studies (Parogene study, NHANES III, DANHES), higher levels of 
serum immunoglobulin (Ig)G against P. gingivalis were associated with periodontitis patients and cardio-
vascular disease (acute coronary syndrome, death from cardiovascular disease and cardiovascular disease). 
The ATHEROREMO-IVUS study failed to demonstrate an association between serum levels of IgG and IgA 
against P. gingivalis, A. actinomycetemcomitans, T. forsythia and P. intermedia and major adverse cardiac 
events (MACE) [24]. This is consistent with data from Boillot et al. [11].
3.7. Do we have evidence that periodontitis patients exhibit dyslipidemia?
There is evidence from systematic reviews that serum total cholesterol levels, low-density lipoproteins 
(LDL), triglycerides, very low-density lipoproteins (VLDL), oxidized LDL and phospholipase A2 are elevated 
in periodontitis. High-density lipoprotein (HDL) levels are reduced in periodontitis patients compared 
with controls (Schenkein & Loos. 2003). These levels are reversed after periodontal therapy [125].
3.8. Do we have evidence for peripheral blood neutrophil hyperresponsiveness in 
reactive oxygen species and protease production in periodontitis patients?
There is strong mechanistic evidence that peripheral blood neutrophils (PBNs) from periodontitis patients 
produce higher levels of total and extracellular reactive oxygen species (ROS) than healthy controls, under 
various conditions of priming and stimulation and from unstimulated cells [66, 74]. This hyper-reactivity to 
stimulation by periodontal bacteria is reduced following successful periodontal therapy to control patient 
levels, but the unstimulated hyperactivity remains, suggesting constitutive and reactive mechanisms 
underlie neutrophil hyper-responsiveness in periodontitis [75]. Gene expression data in PBNs supports the 
functional data [136]. Serum antioxidant levels and those in gingival crevicular fluid (GCF) are reduced in 
periodontitis patients, reflecting increased ROS activity [16]. This data is supported by a study of endarter-
ectomy samples, which demonstrated evidence for activation of the ROS-generating systems in neutrophils, 
specifically the presence of myeloperoxidase (MPO), cell-free DNA and DNA-MPO complexes [99].
3.9. Are there common genetic risk factors between periodontitis and CVDs?
There is scientific evidence of pleiotropy between periodontitis and cardiovascular diseases [1, 83, 111, 112]. 
The highly pleiotropic genetic locus CDKN2B-AS1 (chromosome 9, p21.3) associated with coronary artery 
disease, type 2 diabetes, ischemic stroke and Alzheimer’s disease is also consistently associated with peri-
odontitis [1, 33, 68, 83]. Its function appears to be related to the regulation of gene expression [48]. Interest-
ingly, a pilot study identified that a genetic variant in the CDKN2B-AS1 locus was associated with the extent 
of elevated levels of C-reactive protein in periodontitis [124].
A conserved non-coding element within CAMTA1 upstream of VAMP3, also first identified as a genetic 
susceptibility locus for coronary artery disease, was found to be associated with periodontitis [111]. A GWAS 
suggested the VAMP3 locus was associated with a higher probability of subgingival overgrowth of periodon-
tal pathogens [29].
There is evidence for plasminogen (PLG) as a shared genetic risk factor for coronary artery disease and 
periodontitis [111].
The fourth pleiotropic locus between coronary artery disease and periodontitis is a haplotype block at the 
VAMP8 locus [83].
These shared genetic factors suggest a mechanistic link or immunological commonalities between coro-
nary artery disease and periodontitis. The impairment of the regulatory pathways by genetic factors may be 
a common pathogenic denominator of at least coronary artery disease and periodontitis. There are indica-
tions that aberrant inflammatory reactivity, determined by genetic variants in the loci CDKN2B-AS1 (ANRIL), 
PLG, CAMTA1/VAMP3 and VAMP8 could partially explain the epidemiological link between periodontitis 
and cardiovascular diseases.
4. Evidence from intervention studies
4.1. Is there an effect of periodontitis treatment in preventing or delaying ACVD 
events?
4.1.1. Primary Prevention
There have been no prospective randomized controlled periodontal intervention studies on primary preven-
tion of cardiovascular diseases (including first ischemic events or cardiovascular death) since the last consen-
sus report [128]. The Group questioned the feasibility of performing adequately powered RCTs in primary 
prevention at a population level due to important ethical, methodological and financial considerations.
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However, consistent observational evidence suggests several oral health interventions, including self-
performed oral hygiene habits (toothbrushing) (two studies: [25, 91]), dental prophylaxis (one study: [60]), 
increased self-reported dental visits (one study: [115]) and periodontal treatment (three studies: [47, 60, 91] 
produced a reduction in the incidence of ACVD events.
Cross-sectional data of the Scottish Health Surveys from 1995 to 2003 pertaining to 11,869 men and 
women (mean age of 50 years) was linked to a database of hospital admissions and deaths with follow-up 
until December 2007 (Information Services Division, Edinburgh) [25]. Participants who brushed less than 
once a day exhibited the highest incidence of ACVD events (HR = 1.7, 95% CI [1.3; 2.3]) compared with those 
who brushed twice a day, indicating that self-performed oral hygiene routines may reduce the incidence of 
ACVD.
A retrospective nationwide, population-based study in Taiwan, including 511,630 participants with per-
iodontitis and 208,713 controls, used the Longitudinal Health Insurance Database 2000 to estimate the 
incidence rate of ACVD events from 2000 to 2015 [60]. The hazard ratio for acute myocardial infarction 
was reduced more in the group of periodontitis patients who received dental prophylaxis (HR = 0.90, 95% 
CI [0.86; 0.95]) than intensive treatment (including gingival curettage, scaling and root planing, and/or 
periodontal flap operation and/or tooth extraction) (HR = 1.09, 95% CI [1.03; 1.15]). Consistent reduc-
tions in the incidence rate of Ischemic Stroke were observed in both the dental prophylaxis (HR = 0.78, 
95% CI [0.75; 0.91]) and intensive treatment groups (HR = 0.95, 95% CI [0.91; 0.99]).
A cohort of 8,999 patients with periodontitis who received a complete (non-surgical and if needed surgi-
cal) periodontal treatment protocol were followed between 1979 and 2012 [47]. During the study follow-
up, poor responders to the periodontal treatment had an increased incidence of ACVD events (incidence 
rate –IR = 1.28, 95% CI [1.07; 1.53]) compared with good responders, suggesting successful periodontal 
treatment could reduce the incidence of ACVD events.
In the Atherosclerosis Risk in Communities (ARIC) study, including 6,736 participants followed dur-
ing 15 years, self-reported regular dental care users had a lower risk for ischemic stroke (HR = 0.77, 95% 
CI [0.63; 0.94]) compared to episodic care users [115].
A prospective population-based study using data from the National Health Insurance System-National 
Health Screening Cohort (NHISHEALS), including 247,696 participants free from any CVD history 
recruited between 2002 and 2003, reported an increased number of dental caries lesions, the presence 
of periodontitis and a greater loss of teeth were all associated with an increased risk of future major 
cardiovascular events (MACEs), including cardiovascular death, acute myocardial infarction, heart failure 
and stroke [91]. One additional toothbrushing episode per day was associated with a reduced incidence 
of ACVD events (HR = 0.91, 95% CI [0.89, 0.93]), and regular professional cleaning reduced the risk even 
further (HR = 0.86, 95% CI [0.82; 0.90]).
In summary, progression of ACVD may be influenced by successful periodontal treatment independent 
of traditional CVD risk factor management.
4.1.2. Secondary Prevention
There is only one pilot multi-centre study on secondary prevention of ACVD events (PAVE: [21, 88]), which 
reported no statistically significant difference in the rate of CVD events between patients who underwent 
treatment of periodontitis versus community care (risk ratio –RR = 0.72, 95% CI [0.23; 2.22]). Several meth-
odological limitations highlighted in the trial limit the applicability/usefulness of such evidence to inform 
the research and healthcare communities.
Thus, there is insufficient evidence to support or refute the potential benefit of the treatment of periodon-
titis in preventing or delaying ACVD events [61].
4.2. What is the effect of the treatment of periodontitis in improving surrogate 
parameters of CVD?
Table 1 summarizes the evidence on the effect of periodontal therapy on surrogate markers of CVD. There 
is moderate evidence for reduction of low-grade inflammation as assessed by serum levels of CRP, IL-6 and 
improvements in surrogate measures of endothelial function (flow-mediated dilatation of the brachial 
artery).
Moderate evidence suggests periodontal treatment does not have an effect on lipid fractions, whilst there 
is limited evidence suggesting periodontal treatment reduces arterial blood pressure and stiffness, sub-
clinical ACVD (as assessed by mean carotid Intima-Media-Thickness), and there is insufficient evidence of an 
effect on ACVD biomarkers of coagulation, endothelial cell activation and oxidative stress.
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4.3. What is the effect of statin intake on clinical periodontal outcomes?
Statins are medications prescribed to decrease LDL cholesterol. Numerous trials have demonstrated their 
benefit for the prevention of cardiovascular diseases [141].
Interestingly, statins possess various additional properties relevant to the pathogenesis and treatment 
of periodontitis [34]. In particular, it has been reported that statins are anti-inflammatory [54, 94, 97, 
102, 106], can promote bone formation [41, 67, 81, 134], can inhibit matrix metalloproteinases (MMPs) 
[54, 71, 96] and possess anti-microbial properties [126].
A systematic review with meta-analysis of pre-clinical in vivo trials reported a positive effect of local or 
systemic statin administration for the prevention of alveolar bone loss in experimental periodontitis models 
in rodents [9].
Several observational clinical studies have evaluated the effect of systemic statin intake on periodontal 
conditions [65, 76, 107, 109, 110, 123]. Statin use was not found to be associated with decreased tooth loss 
in adults with chronic periodontitis when analysing administrative health plan data [109]. However, a five-
year population-based follow-up study comparing participants treated with statins with those who did not 
medicate with statins concluded long-term treatment with statins was associated with reduced tooth loss 
[76]. Furthermore, patients on statin medication were reported to exhibit significantly fewer signs of peri-
odontal inflammatory lesions than patients without a statin regimen [65]. A cross-sectional study compared 
the periodontal status of patients with hyperlipidaemia (with or without statin intake) to normolipidaemic 
individuals and found higher gingival bleeding and probing depths in the hyperlipidaemic patients who 
were not statin users [107]. In an RCT, periodontal patients with risk factors or with established atherosclero-
sis were assigned to either a high or low dose statin intake [123]. After three months, a significant reduction 
of periodontal inflammation was seen in the high-dose compared to the low-dose group. Thus, within the 
limits of the above reported studies, there is some limited evidence suggesting statins may have a positive 
impact on periodontal health.
Very few clinical studies have been designed to evaluate the effect of adjunctive systemic statin intake in 
conjunction with periodontal therapy [35, 36, 108]. In a randomized placebo-controlled pilot study in 38 
patients with chronic periodontitis, adjunctive statin intake led to beneficial effects on radiological bone 
loss and tooth mobility after 3 months [35]. Another 3 month-study compared the treatment response to 
nonsurgical periodontal therapy in 107 chronic periodontitis patients (35 normolipidemic as control, 36 
Table 1: Summary of the evidence on the effect of periodontal therapy on surrogate markers of cardio-
vascular diseases.
Topic Outcome Number of RCTs 
and SR since 
last consensus
References Effect Overall 
Level of 
Evidence
Effect of Periodontal Therapy 
on Lipids
Lipids ( multiple) 6 RCTs [12, 22, 26, 38, 
44, 51]
No Moderate
Effect of Periodontal Therapy 
on Blood Pressure
Systolic, diastolic 3 RCTs [22, 44, 142] Yes Limited
Effect of  Periodontal Therapy 
on  Endothelial Function
Endothelial Function 
(multiple measures)
2 RCTs [22, 105] Yes Moderate
1 SR [122]
Effect of  Periodontal Therapy 
on  interleukin (IL)-6
IL-6 3 RCTs [38, 51, 142] Yes Moderate
Effect of Periodontal Therapy 
on C-Reactive Protein (CRP)
CRP 5 SR [27, 37, 49, 90, 
125]
Yes Moderate
7 RCTs following 
2014
[12, 22, 26, 44, 
51, 53, 142]
Effect of Periodontal Therapy 
on Pulse Wave Velocity (PWV)
PWV 1 RCT [51] No Limited
Effect of Periodontal Therapy 
on carotid Intima-Media 
 Thickness (c-IMT)
Common c-IMT 1 RCT [51] Yes Limited
RCT, randomised clinical trial; SR, systematic review.
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hyperlipidaemic on nonpharmacological therapy and 36 hyperlipidemic on statins) and found a greater 
improvement in gingival index in the nomolipidemic control and in the statin groups [108]. Based on this 
limited evidence, two recent systematic reviews with meta-analysis on the effects of (local and systemic) 
statins on periodontal treatment concluded systemic statin intake does not enhance the outcomes of peri-
odontal therapy [8, 82].
5. Cardiovascular risks and complications of periodontal therapeutic 
interventions
5.1. Is there an ischemic cardiovascular risk for patients undergoing periodontal 
therapy?
Non-surgical treatment of periodontitis involving supra- and sub-gingival instrumentation of the affected 
dentition (under local anaesthesia) is often delivered in several short sessions. Alternatively, full-mouth non-
surgical periodontal treatment can be performed within 24 hours.
Delivering periodontal treatment in a full-mouth fashion (i.e., within 24 hours) triggers a one-week acute 
systemic inflammatory response associated with a transient impairment of endothelial function [89]. This 
distant effect is not observed when periodontal treatment is delivered across several separate sessions [42]. 
This is achieved by limiting the number of teeth involved and the time devoted to completing the dental 
instrumentation. These findings raise the question of whether performing longer sessions of periodontal 
treatment could contribute to an individual’s inflammatory burden/risk and increase their short-term risk 
of suffering from a vascular event. There is consistent and strong observational evidence that common acute 
infections/inflammatory responses are associated at a population level with an increased risk of vascular 
events within the first four weeks of the infectious/inflammatory event [120].
5.1.1. At population level
There is no evidence for specific effects of periodontal treatment procedures on increasing ischemic cardio-
vascular risk. Two observational studies reported no effect of invasive dental treatment in elevating ischemic 
cardiovascular risk [19, 86], and one study suggested a minimal increased risk within four weeks following 
treatment [79].
Chen et al. [19] performed a case-crossover and self-controlled case series using the Taiwanese National 
Health Insurance Research Database, including over 110,000 myocardial Infarction cases and 290,000 
Ischemic Stroke patients, between 1999 and 2014. They reported a non-significant increase in the incidence 
of myocardial infarction within the first 24 weeks following invasive dental treatment (including periodontal 
procedures) except for a modest risk of myocardial infarction during the first week for patients without 
other comorbidities (OR = 1.31, 95% CI [1.08; 1.58], after 3 days).
A registry-based case-control study between 2011 and 2013 including 51,880 cases who underwent an 
invasive dental procedure compared to 246,978 controls reported no association with increased incidence of 
myocardial infarction (OR 0.98, 95% CI [0.91; 1.06]) [86].
Minassian et al. [79] performed a self-controlled case series including nearly 10 million participants 
included in an insurance database from 2002 and 2006 in the USA. The analysis showed that invasive 
dental treatment (largely comprising of tooth extractions and only 4% being non-surgical and surgical peri-
odontal procedures) is associated with an increased risk of incident acute cardiovascular events (IR = 1.5, 
95% CI [1.09; 2.06]) within the first four weeks of treatment recorded.
In summary, the Group concluded delivering periodontal treatment is safe with regard to cardiovas-
cular risk.
5.1.2. In patients with established CVD
There is limited evidence on the effects of invasive dental treatment on the incidence of Ischemic Events in 
patients with established CVD or after an event.
A small RCT on the effects of the treatment of periodontitis on CVD biomarkers in patients with estab-
lished CVD [80] showed no cardiovascular adverse events within three months of completion of scaling and 
root planing (periodontal therapy).
In the PAVE feasibility randomized secondary prevention trial, provision of periodontal scaling and root 
planing treatment in patients with established CVD did not increase the incidence of cardiovascular events 
compared to the control group (community treatment) within six months [6].
In summary, the Group concluded delivering periodontal treatment is safe with regards to cardiovascular 
risk in patients with established CVD.
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5.2. What is the perioperative bleeding risk when performing periodontal  therapy?
Periodontal treatment consists of numerous procedures with different levels of bleeding risk. However, this 
risk of bleeding is low in the vast majority of procedures and can be easily controlled with local haemostatic 
measures.
Perioperative bleeding risk varies according to the extent and invasiveness of the periodontal procedure 
performed. The majority of periodontal procedures may be grouped within the ESC/AHA/EHRA [121, 122]. 
Low Bleeding Risk (frequency less than 1% of post-operative bleeding) group: supragingival polishing, non-
surgical periodontal treatment, conventional surgical periodontal treatment (conservative, resective or 
regenerative), tooth extractions and dental implant placement. Moderate bleeding risk (frequency between 
2–5%) may be observed in major autogenous bone augmentation procedures, such as block bone harvest-
ing, sinus floor elevation and procedures where healing is by secondary intention, such as free gingival graft-
ing. Appendix 1 summarizes the main recommendations for patients with antithrombotic therapy when 
perfoming periodontal therapy.
5.2.1. In patients undergoing anti-platelet therapy
Individuals undergoing single acetylsalicylic acid (ASA) therapy (aspirin) in different therapeutic dosages, 
as well as therapy with clopidogrel, ticlopidine or ticagrelor show no statistically significant differences in 
frequency of bleeding events when compared to controls (i.e., subjects not undergoing anti-platelet therapy) 
[30, 62].
Dual antiplatelet therapy, most commonly ASA in combination with clopidogrel, may pose a certain risk 
for postoperative bleeding complications; however, it appears these haemorrhagic events may be managed 
safely with local haemostatic measures [84, 85].
Thus, current evidence does not support discontinuation of antiplatelet therapy before dental procedures, 
irrespective of the type of therapy employed (single or dual antiplatelet therapy) or the type of procedure 
performed (single, multiple tooth extractions, non-surgical and surgical periodontal therapy and dental 
implant procedures).
5.2.2. In patients undergoing anti-coagulant therapy
5.2.2.1. Vitamin-K antagonists
In patients taking oral anticoagulant therapy (vitamin-K antagonists, VKA) and undergoing dental extrac-
tion, minor dental procedures and dental implant placement do not seem to increase the risk of bleeding 
compared to patients who discontinue oral anticoagulant therapy [118, 139]. There may be a higher post-
operative bleeding risk in patients continuing VKA and undergoing either minor dental surgery or other 
higher-risk procedures when compared to non-VKA patients [10, 118], but local haemostatic agents appear 
to be effective in controlling post-operative bleeding [72].
5.2.2.2. Novel/direct anticoagulants (DOAC/NOAC)
Limited trials and evidence are available on the management of patients on novel oral anticoagulant (NOAC) 
therapy undergoing dental treatment; hence, the Group concluded further studies regarding dental proce-
dures in these patients are strongly encouraged.
It appears there is no need for interruption of NOAC therapy in most dental treatments due to a low 
incidence of bleeding complications, which can be successfully managed with local haemostatic measures 
when comparing groups continuing NOAC and groups discontinuing NOAC therapy [58, 59, 92, 137], and 
with reported timing of discontinuation and reinstitution varying greatly. When comparing NOAC patients 
with healthy individuals, there seems to be a higher incidence of delayed bleeding (2 days and later) in those 
patients who do not discontinue NOAC therapy [78].
6. Recommendations
6.1. Recommendations for oral health professionals for use in dental practice/office 
for people with cardiovascular disease (CVD)
•	 Patients with periodontitis should be advised there is a higher risk for cardiovascular diseases, such 
as myocardial infarction or stroke, and as such they should actively manage all their cardiovascular 
risk factors (smoking, exercise, excess weight, blood pressure, lipid and glucose management and 
sufficient periodontal therapy and periodontal maintenance).
•	 Patients with periodontitis and a diagnosis of CVD should be informed they may be at higher risk 
for subsequent CVD complications and, therefore, they should regularly adhere to the recommend-
ed dental therapeutic, maintenance and preventive regimes.
Sanz et al: Periodontitis and Cardiovascular Diseases. Consensus Report Art. 1, page 11 of 23
•	 Collect a careful history to assess for CVD risk factors, such as diabetes, obesity, smoking, hyperten-
sion, hyperlipidemia and hyperglycemia. Suggestthe patient consults his/her physician if any of 
these risk factors are not appropriately controlled.
•	 Oral health education should be provided to all patients with periodontitis and a tailored oral hy-
giene regime, including twice-daily brushing, inter-dental cleaning and in some cases the use of 
adjunctive chemical plaque control may be appropriate.
•	 People presenting with a diagnosis of CVD should receive a thorough oral examination, which 
embeds a comprehensive periodontal evaluation, including full-mouth probing and bleeding 
scores.
•	 If no periodontitis is diagnosed initially, patients with CVD should be placed on a preventive care 
regime and monitored regularly (at least once a year) for changes in periodontal status.
•	 In people with CVD, if periodontitis is diagnosed, they should be managed as soon as their cardio-
vascular status permits.
•	 Irrespective of the level of CVD or specific medication, non-surgical periodontal therapy should 
be provided, preferably in several 30–45 minute sessions to minimize a spike of acute systemic 
inflammation
•	 Surgical periodontal and implant therapy, when indicated, should be provided in a similar manner 
as in patients without CVD.
However, attention should be paid to:
•	 Hypertension. It is recommended to measure the patients’ blood pressure (after appropriate re-
laxation) before the surgical intervention, and in cases of high blood pressure (above 180/100 
according to expert opinion), the surgery should be postponed until the patient’s blood pressure 
is stabilized.
•	 Medication with antiplatelet and anticoagulant drugs. Because periodontal and implant surgical 
procedures usually impart only a low to medium risk of bleeding in general terms, the dentist 
should not change a patient’s medication or in cases of doubt he/she should consult the physi-
cian/cardiologist prior to the surgical intervention. Consideration should also be given to the 
local management of bleeding complications that may arise.
Current AHA/ACC/SCAI/ACS/ADA/ESC/ACCP guidelines on perioperative management of antithrom-
botic therapy do not suggest discontinuation of anti-platelet therapy for Low Bleeding Risk procedures 
[32, 43, 57].
Various approaches for perioperative management of anticoagulant therapy have been suggested. The 
Group reviewed the guidelines on perioperative management of vitamin K antagonists (VKA) and suggests 
discontinuation of medication treatment if the INR is 4 or below for Low or Medium Bleeding Risk proce-
dures [95]. However, if the internationalised normalised ratio (INR) is 3.5 or above, the expert Group recom-
mends dental clinicians seek advice and consult with the responsible medical professional. Management 
of high thromboembolic risk cases should be collaborative in consultation with the medical professional 
responsible for the VKA therapy [57, 130].
After reviewing novel anticoagulant (non VKA) and direct anticoagulant (NOAC/DOAC) therapies guide-
lines, the Group concluded that for Low Bleeding Risk periodontal procedures no discontinuation of antico-
agulants is recommended [121, 122]. These procedures could be performed 18–24 hrs after the last intake 
(depending on a renal function assessment for the medication in question) and then restarted 6 hrs fol-
lowing treatment. The expert Group, however, strongly recommends the dental clinician consult with the 
responsible medical professional. When a Medium Bleeding Risk periodontal procedure is planned, discon-
tinuation of therapy should be agreed with the medical professional responsible for and/or prescribing the 
anticoagulant therapy.
Lastly, in cases of combined anti-platelet and anticoagulant therapies, which pertain to patients with the 
highest thrombotic and ischemic risk (i.e., chronic atrial fibrillation or after an acute myocardial infarction 
or recent coronary stenting), when periodontal procedures (either of Low or Medium Bleeding Risk) are 
required, any alterations in medication should be discussed and agreed upon with the responsible medical 
professional [121, 122]. In elective periodontal procedures, the operation should be delayed until after treat-
ment stabilization and appropriate consultation with the medical specialist.
In cases of triple therapy (dual anti-platelet and one anticoagulant) or one anticoagulant plus one anti-
platelet, such patients need individualised management by the responsible medical professional according 
to their thrombotic and haemorrhagic risk [130].
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It is important to highlight that local haemostatic agents (such as oxidised cellulose, absorbable gel-
atin sponges, sutures, tranexamic acid mouthwashes, compressive gauze soaked in tranexamic acid) 
should be used and dental clinicians should consider the confounding effect of local anaesthetic with 
vasoconstrictors.
•	 Patients with a risk of endocarditis should be premedicated with antibiotics following current 
guidelines (such as the European or the American guidelines).
•	 People with cardiovascular disease who have extensive tooth loss should be encouraged to pursue 
dental rehabilitation to restore adequate mastication for proper nutrition.
•	 People without a diagnosis of CVD but with risk factors for CVD should be informed about their 
CVD risk and referred to a physician for appropriate risk assessment, diagnostic testing and follow-
up care. For oral health professionals, risk assessment may be performed based upon the recom-
mendations of the European Society of Cardiology (Systematic COronary Risk Evaluation, SCORE) 
[119].
6.2. Recommendations for physicians and other medical health professions for 
use in cardiology practice
Because of the potential negative impact of periodontitis on CVD complications, the following recommen-
dations are made:
•	 Patients with CVD should be advised periodontitis may have a negative impact on CVD and may also 
increase the risk of CVD events.
•	 Patients should be advised effective periodontal therapy may have a positive impact upon CV  
health.
•	 For people with CVD, physicians should ask about a prior diagnosis of periodontitis. If a positive 
diagnosis has been made, the physician should seek to ascertain that appropriate periodontal care 
and maintenance are being provided.
•	 Patients with CVD should be asked about any signs and symptoms of periodontitis, including bleed-
ing gums during brushing or eating, loose teeth, spacing or spreading/drifting of the teeth, oral 
malodor and/or abscesses of the gums or gingival suppuration.
 ◦ If a positive history is elicited, then a prompt periodontal evaluation should be recommended 
before their scheduled annual check-up.
 ◦ In the case of a negative history, people with CVD should be advised to check for the above 
symptoms, and if a positive sign appears, they should visit their dentist at least once per  
year.
•	 For all patients with newly diagnosed CVD, referral for a periodontal examination should occur as 
part of their ongoing management of CVD. Even if no periodontitis is diagnosed initially, an annual 
oral/dental check-up is recommended.
•	 The physician should liaise with the dental surgeon over periodontitis management in CVD patients 
on anticoagulant/antiplatelet therapy prior to the oral intervention and/or periodontal surgery to 
avoid excess bleeding or the risk of ischaemic events.
6.3. Recommendations for patients at the dental surgery/office who have CVD or 
are found to be at risk of CVD
•	  People with CVD must be aware that gum disease is a chronic condition, which may aggravate their 
CVD, and requires lifelong attention and professional care.
•	 There is a need to clean the teeth and gums very carefully at home. Personalized advice will be pro-
vided by the oral health professional.
This may include
•	 Twice-daily brushing with either a manual or electric toothbrush;
•	 Cleaning between teeth using inter-dental brushes where they fit; where they do not fit, then floss-
ing may be useful;
•	 Use of specific dentifrices and/or mouth rinses with proven activity against dental plaque, if advised 
by oral health professionals;
•	 If left untreated, gum disease can lead to tooth loss and may also make CVD preventive measures 
harder to control;
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•	 Gum disease may be present and deteriorate with no apparent symptoms, so the dentist should 
advise their patient that even without current gum disease, they should still receive regular dental 
check-ups as part of managing their CVD.
Dentists should be able to identify the early signs of gum disease, but patients should also suspect gum 
disease if noticing
•	 Red or swollen gums;
•	 Bleeding from the gums or blood in the sink after tooth brushing;
•	 Foul taste;
•	 Longer looking teeth;
•	 Loose teeth;
•	 Increasing spaces between teeth/teeth moving apart;
•	 Calculus (tartar) on teeth.
Patients should inform their dentist about the outcome of their visits to the physician and provide an 
update on their CVD history and any changes in medications. Patients should inform the dentist if they are 
on anticoagulant therapy.
Patients should understand it is important to keep their mouth and whole body as healthy as possible 
with regular dental and medical visits.
6.4. Recommendations for patients with CVD at the physician’s practice/office
6.4.1. Why should I have my gums checked?
If your physician has told you that you have cardiovascular disease (CVD), you should make an appointment 
with a dental surgeon to have your mouth and gums checked.
This is because people with CVD may have a higher chance of getting further complications when they 
have gum disease. The earlier you seek help, the better the outcome will be.
6.4.2. What should I look for that may tell me I have problems with my gums?
You may have gum disease if you have ever noticed
•	 Red or swollen gums;
•	 Bleeding from your gums or blood in the sink after you brush your teeth;
•	 Foul taste;
•	 Longer looking teeth;
•	 Loose teeth;
•	 Increasing spaces between your teeth, or your teeth drifting apart;
•	 Calculus (tartar) on your teeth.
If you have noticed any of these problems, it is important to see a dentist as soon as possible.
6.4.3. Can I have gum disease without these signs being present?
Gum disease may also be present and get worse with no apparent that you have it, especially if you smoke, 
so even if you do not think you have gum disease now, you should still have annual check-ups of your mouth 
as part of managing your CVD. Your dentist will be able to pick up early signs of gum disease.
6.4.4. What can I do to prevent gum disease?
You need to clean your teeth and gums twice daily at home for a minimum of two minutes. Also, cleaning 
between your teeth daily is important, and your oral health professional will show you how to do this. You 
should visit a dental surgeon as soon as possible for a diagnosis and advice on what you need to do. It is 
important to keep your mouth as healthy as possible with regular oral and dental care, according to the 
recommendations of your oral health professional.
Additional File
The additional file for this article can be found as follows:
•	 Supplementary Appendix 1. Antithrombotic therapy: when, how and why. Comprehensive  approach 
for oral health professionals. DOI: https://doi.org/10.5334/gh.400.s1
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